TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07227818: A Phase 3, Multicenter, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Assess the Efficacy of NBI-1117568 in Preventing Relapse of the Symptoms of Schizophrenia and to Assess the Safety and Tolerability

Sponsor: Neurocrine Biosciences · Phase: PHASE3 · Area: CNS_NEUROLOGY · Target Enrollment: 560 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$4,628,064

Rescue Site Savings

+$3,030,280

Unlock Full NCT07227818 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07227818 Rescue Dossier →